Greece limits use of AstraZeneca vaccine to people over 30
Greece limits use of AstraZeneca vaccine to people over 30
Europe's medicines regulator said this week it found rare cases of blood clots among some adult recipients of the shot, although the vaccine's advantages still outweighed its risks.
"The National Vaccination Committee, after evaluating all available data, recommends the continuation of the vaccination programme with all available vaccines, including the AstraZeneca vaccine, to people aged 30 and over," the committee said in a statement.
The risk of a serious illness and death from COVID-19 "overwhelmingly" outweighed the risk of a possible blood clot following vaccination, especially for ages over 30, it said.
Greece has reported 288,230 cases of COVID-19 and a total of 8,680 deaths. It has administered 378,997 doses of the AstraZeneca vaccine so far and ordered another 1.35 million doses.
It has also used the Pfizer and Moderna COVID-19 vaccines to inoculate more than 2 million people.
Vaccination programmes have stuttered in Europe and elsewhere in the last month, since a very few mostly young recipients of the AstraZeneca shot were found to have suffered extremely unusual blood clots, leading some countries to suspend its use as a precaution or restrict it to people above a certain age.
Germany was the first European country to recommend that people under 60 who have had a first AstraZeneca shot should receive a different product for their second dose.
(Reporting by Angeliki Koutantou; Editing by Angus MacSwan)
((angeliki.koutantou@thomsonreuters.com; +30 2102214608;
Reuters Messaging: angeliki.koutantou.reuters.com@reuters.net)
ATHENS, April 9 (Reuters) - Greece will limit use of the AstraZeneca COVID-19 vaccine to people above age 30 following rare cases of blood clots, its national vaccinations committee said on Friday, falling into line with other European countries.
Europe's medicines regulator said this week it found rare cases of blood clots among some adult recipients of the shot, although the vaccine's advantages still outweighed its risks.
"The National Vaccination Committee, after evaluating all available data, recommends the continuation of the vaccination programme with all available vaccines, including the AstraZeneca vaccine, to people aged 30 and over," the committee said in a statement.
The risk of a serious illness and death from COVID-19 "overwhelmingly" outweighed the risk of a possible blood clot following vaccination, especially for ages over 30, it said.
Greece has reported 288,230 cases of COVID-19 and a total of 8,680 deaths. It has administered 378,997 doses of the AstraZeneca vaccine so far and ordered another 1.35 million doses.
It has also used the Pfizer and Moderna COVID-19 vaccines to inoculate more than 2 million people.
Vaccination programmes have stuttered in Europe and elsewhere in the last month, since a very few mostly young recipients of the AstraZeneca shot were found to have suffered extremely unusual blood clots, leading some countries to suspend its use as a precaution or restrict it to people above a certain age.
Germany was the first European country to recommend that people under 60 who have had a first AstraZeneca shot should receive a different product for their second dose.
(Reporting by Angeliki Koutantou; Editing by Angus MacSwan)
((angeliki.koutantou@thomsonreuters.com; +30 2102214608;
Reuters Messaging: angeliki.koutantou.reuters.com@reuters.net)
雅典,4月9日(路透社)-希臘國家疫苗接種委員會週五表示,在罕見的血栓病例之後,希臘將限制阿斯利康新冠肺炎疫苗的使用,僅限於30歲以上的人,這與其他歐洲國家一致。歐洲藥品監管機構本週表示,他們在一些成年疫苗接受者中發現了罕見的血栓病例,儘管疫苗的好處仍然大於風險。該委員會在一份聲明中説:“國家疫苗接種委員會在評估了所有可用的數據後,建議繼續為30歲及以上的人羣接種包括阿斯利康(AstraZeneca)疫苗在內的所有可用疫苗。”報告稱,新冠肺炎導致嚴重疾病和死亡的風險“壓倒性地”超過了接種疫苗後可能出現血栓的風險,特別是對於30歲以上的人。希臘已經報告了288,230例新冠肺炎病例,總共有8,680人死亡。到目前為止,它已經接種了378,997劑阿斯利康疫苗,並訂購了135萬劑。它還使用輝瑞和現代新冠肺炎疫苗為200多萬人接種了疫苗。上個月,歐洲和其他地方的疫苗接種計劃陷入停滯,因為極少數接受阿斯利康(AstraZeneca)注射的人被發現患有極其不尋常的血栓,其中大部分是年輕人,這導致一些國家暫停使用,作為預防措施,或者僅限於一定年齡以上的人使用。德國是第一個建議60歲以下的人在第二次注射阿斯利康(AstraZeneca)疫苗時應該服用不同產品的歐洲國家。(Angeliki Koutantou報道;Angus MacSwan編輯)(angeliki.koutantou@thomsonreurs.com;+30 2102214608;路透社消息:angeliki.koutantou.reurs.com@reurs.net)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧